Highlights

  • EMVision is developing portable, non-invasive brain scanners for time-sensitive neurological assessment.
  • The emu bedside brain scanner remained in a pivotal validation trial during 2026.
  • First Responder research has assessed feasibility and usability in aeromedical settings.
  • The company is examining an additional acute ischaemia detection endpoint for its pivotal trial.
  • Both products remain investigational and are not available for clinical use or sale.

EMVision Medical Devices Limited (ASX:EMV) develops portable, non-invasive neurodiagnostic technology intended to bring brain assessment closer to patients. Its work centres on the emu bedside scanner and a separate First Responder concept for use before hospital arrival. During 2026, EMVision continued clinical evaluation and product development, with the distinction between research progress and regulatory authorisation remaining central to its reporting.

Bedside Scanning and the emu Trial

The emu system is designed for point-of-care assessment in settings where moving a patient for conventional imaging may be difficult or time-consuming. EMVision Medical Devices (ASX:EMV) describes a movable unit with a headset, standardised positioning and a push-to-scan workflow. The technology does not use ionising radiation, and its intended role is being tested rather than assumed from the product design.

A March 2026 company update reported seven stroke hospitals actively recruiting into the pivotal trial, with further hospital activation under way. In its July 2026 quarterly disclosure, EMVision (ASX:EMV) said recruitment had passed key milestones. Its August FY2026 presentation described completion of enrolment as a target for early calendar 2027, followed by trial readouts and a potential US regulatory submission. These are planned steps, not completed approvals.

Investigating Stroke Classification

A key objective is to provide information that could help distinguish clinically important brain conditions more quickly. EMVision (ASX:EMV) reported preparations in 2026 to seek the addition of an acute ischaemia detection endpoint to its pivotal study. That proposed amendment remained subject to engagement with the US Food and Drug Administration and the relevant study process. It should not be described as an established diagnostic capability.

Validation must show that diagnostic outputs are reproducible and clinically meaningful; scanning speed alone does not establish accuracy.

First Responder Research Outside Hospital

The separate First Responder programme considers whether lightweight brain-scanning equipment could be used in road and air ambulance environments. EMVision (ASX:EMV) announced the completion of an aeromedical feasibility and usability study in 2026. The study addressed practical issues such as setup, operation and use during retrieval, rather than providing evidence of an approved pre-hospital stroke diagnosis service.

In its FY2026 presentation, the company reported a median scan time of approximately five minutes in the aeromedical feasibility work and favourable operator feedback. It also indicated that a first commercial-production-equivalent device build was planned for early 2027. Engineering readiness, clinical validation and any applicable regulatory clearance remain separate stages of development.

Development Priorities and Practical Constraints

For EMVision (ASX:EMV), the central tasks include recruitment and data quality in the pivotal study, further evaluation of detection algorithms and development of hardware suitable for demanding clinical environments. The company has also referred to a regional benefits study intended to examine the potential usefulness of bedside scanning where access to conventional imaging may be delayed.

Further studies, manufacturing and potential deployment involve trial coordination, training, maintenance and quality systems. These stages do not constitute commercial adoption.

Key Insights

EMVision Medical Devices (ASX:EMV) is pursuing two related but distinct applications of portable brain imaging: bedside hospital assessment and assessment in pre-hospital settings. Its 2026 updates document trial activity, feasibility research and continued product development. The principal distinction is between intended clinical benefits and benefits confirmed through validation: neither the emu nor First Responder device was presented by the company as available for sale or clinical use.